SynthesisBMC cardiovascular disorders2024
Prognostic value of anion gap for patients with heart failure: a systematic review and meta-analysis.
Synthesis in BMC cardiovascular disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The association of albumin-corrected anion gap and acute kidney injury in heart failure patients: a competing risk model analysis.BMC cardiovascular disorders · 2025Article
- Relationship between albumin-corrected anion gap and short- and medium-term all-cause mortality in heart failure patients with a single ICU admission.Frontiers in cardiovascular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart failure (HF) is among the cardiovascular diseases with high morbidity and mortality worldwide. Due to the high burden of HF, finding easy-to-use prognostic factors has become important. Studies have investigated the correlation between anion gap (AG) and the HF prognosis. In this systematic review and meta-analysis, we aimed to evaluate the association between AG association with HF prognosis.
methodsPubMed, Embase, Scopus, and the Web of Science were systematically searched for studies evaluating AG in HF prognosis. Standardized mean difference (SMD) and pooled hazard ratio (HR) in addition to 95% confidence intervals (CIs) were calculated using random-effect meta-analyses to compare survivors vs. non-survivors.
resultsNine studies were included in this systematic review. In a random-effect meta-analysis comparing AG levels in those who died and survivors, non-survivors had significantly higher levels of AG (SMD 0.57, 95% CI 0.42 to 0.71, P < 0.0001, I
conclusionThis study found that higher AG levels are associated with higher mortality in patients with HF which could be used in clinical settings and for patient management due to its ease of measurement and calculation. If confirmed in future studies, using this easy-to-measure index in clinical settings could provide useful information for clinicians in determining the risk of HF patients. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.